Remimazolam: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan) recommended or restricted remimazolam, while CIPM (Spain), NYE METODER (Norway) and SMC (Scotland) did not recommend it.
Assessment has run over 6.1 years, from 20 May 2020 at CHUIKYO (Japan) to 18 Jun 2026 at G-BA (Germany).
No assessment is on file from HAS (France), PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for remimazolam, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 6 of 9 records date from 2023 or later.
Against its own class, remimazolam is an outlier: 20% of its decisive outcomes were positive, where molecules sharing ATC class N05C average 71%.
CHUIKYO (Japan) was first to assess remimazolam, on 20 May 2020; G-BA (Germany) did not open a file until 18 Jun 2026 — a wide spread of 6.1 years between the earliest and latest system to look at it.
3 of the 6 agencies here assessed remimazolam more than once, G-BA (Germany) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for remimazolam.
The full ledger for remimazolam reads 4 not recommended, 2 no benefit, 1 non-submission and 1 not assessed, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 18 Jun 2026 | Byfavo — benefit assessment §35a | added benefit: not proven | source |
| CIPM (Spain) | 20 Nov 2024 | Indicación terapéutica autorizada: Remimazolam está indicado en adultos para sedación de procedimiento. Condiciones de p… | not financed by the SNS · art. 92 d, e | source |
| SMC (Scotland) | 8 Jul 2024 | In adults for intravenous induction and maintenance of general anaesthesia. | not recommended | source |
| NYE METODER (Norway) | 12 Mar 2023 | Sedasjon ved diagnostiske eller kirurgiske prosedyrer | not introduced | source |
| AWMSG (Wales) | 14 Apr 2021 | Use in adults for procedural sedation | outside AWMSG criteria | source |
4 further decisions for remimazolam, across 4 agencies, are not shown here. They include the most recent record on file, 18 Jun 2026 from G-BA (Germany); its outcome is in the subscriber dataset. They link to 4 further source documents.
Related molecules
- melatonin — same ATC class N05C — Psycholeptics
- midazolam — same ATC class N05C — Psycholeptics
- dexmedetomidine — same ATC class N05C — Psycholeptics
- daridorexant — same ATC class N05C — Psycholeptics
- zolpidem — same ATC class N05C — Psycholeptics
- guselkumab — also decided by G-BA in 2026Q2
Coverage: 9 decisions for remimazolam from 6 agencies, 2020 to 2026. Data to 7 Sep 2026. ATC class N05C — Psycholeptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.